Apexigen, Inc.

Apexigen, Inc. (ticker: APGN) is a clinical-stage biopharmaceutical company focused on developing novel antibody-based cancer immunotherapies, which entered public markets through a de-SPAC transaction sponsored by Brookline Capital Acquisition Corp. The company filed a 10-Q quarterly report on June 7, 2021, under accession number 0001193125-21-183271, reflecting its reporting activity ahead of the de-SPAC closing. Operating in the oncology and biotechnology sector, Apexigen has pursued a pipeline of immune-activating and immune-inhibiting antibody candidates intended to address unmet needs across multiple tumor types. For full filing history, transaction timelines, and comparative SPAC analytics on APGN and hundreds of similar deals, create a free account on SpacDesk.